Journal of Jishou University(Natural Sciences Edition)

• Medical Science • Previous Articles     Next Articles

Efficacy and Safety of Nab-Paclitaxel for Relapsed Extensive-Stage Small-Cell Lung Cancer

XU Chaojiu, ZHAO Jingsheng, CHEN Chaoying, LONG Jian, LIANG Jing   

  1. (Department of Oncology, People's Hospital of Xiangxi Autonomous Prefecture, Jishou 416000, Hunan China)
  • Online:2020-03-25 Published:2020-09-08


The clinical efficacy and adverse effects of nab-paclitaxel in patients with relapsed extensive-stage small-cell lung cancer have been researched. Clinical data of 24 relapsed extensive-stage small-cell lung cancer patients who received nab-paclitaxel as single agent between June 2017 and June 2019 were collected, and the curative and adverse effects of the compound were evaluated.  All patients were treated with 130 mg/m nab-paclitaxel on days 1, 8, and 15. The cycle was repeated every 4 weeks. Clinical efficacy was evaluated every two cycles. Results showed that among 24 patients, including 18 males and 6 females, the median age being 65 years (range 45~77 years), 8 patients (33.3%) achieved partial response, 7 patients (29.2%) had a stable disease, and 9 patients (37.5%) had progressive disease. The objective response rate was 33.3%, and the disease control rate was 62.5%. The median progression-free survival was 3.6 months and median overall survival was 8.3 months. The major adverse reactions included  neutropenia (37.5% ), alopecia (29.2% ), and sensory neuropathy (16.7% ). It can be concluded that nab-paclitaxel has curative effects, and its adverse effects are tolerable. Further research with a larger sample size is warranted to confirm these results.

Key words: nab-paclitaxel, extensive-stage small-cell lung cancer, chemotherapy

WeChat e-book chaoxing Mobile QQ